 |
Case Report
Eight-year follow-up of a patient with glioblastoma multiforme who completed radical treatment
1 National Cancer Institute, Maria Skłodowska- Curie Memorial Institute, Kraków Branch, Poland
2 Institute of Medical Sciences, Medical College of Rzeszow University Rzeszow, Poland
3 Department of Anatomy, Jagiellonian University, Medical College, Kraków, Poland
4 National Cancer Institute, Maria Sk?odowska- Curie Memorial Institute, Kraków Branch, Poland
Address correspondence to:
Aleksandra Grela-Wojewoda
National Cancer Institute, Maria Skłodowska-Curie Memorial Institute, Kraków Branch,
Poland
Message to Corresponding Author
Article ID: 100060Z09AW2021
Access full text article on other devices
Access PDF of article on other devices
How to cite this article
Grela-Wojewoda A, Kruczała M, Pacholczak-Madej R, Łuczyńska E, Niemiec J, Mucha-Małecka A. Eight-year follow-up of a patient with glioblastoma multiforme who completed radical treatment. J Case Rep Images Med 2021;7:100060Z09AW2021.ABSTRACT
The aim of the study is the presentation of an unexpectably long, eight year survival of a female patient, suffering from glioblastoma multiforme (GBM), who completed radical treatment, which was composed of neurosurgery followed by radiochemotherapy with temozolomide. The condition of the patient was regularly examined and brain computed tomography was performed to exclude recurrence of the disease. During eight years of follow-up, no relapse was observed. After radical treatment, the neurological condition of the patient systematically improved. At present, as a result of rehabilitation, neurological symptoms are not observed. Currently, the patient does not require any drugs, including anticonvulsants. In conclusion, despite extremely unfavorable prognosis, every patient who is fit enough should receive radiochemotherapy with temozolomide after neurosurgery, because long-term survival in GBM is achievable. In case of technical difficulties (unavailable radiotherapy or chemotherapy in smaller hospitals) patients should be referred to oncology centers for combined treatment.
Keywords: Glioblastoma multiforme (GBM), Radical treatment, Radiochemotherapy, Temozolomide
SUPPORTING INFORMATION
Acknowledgments
I would like to thank Professor D. Adamek, who undertook the reassessment of the archival histopathological material, which made it possible to re-confirm the diagnosis of GLB IV.
Author ContributionsAleksandra Grela-Wojewoda - Substantial contributions to conception and design, Acquisition of data, Analysis of data, Interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Maksymilian Kruczała - Substantial contributions to conception and design, Acquisition of data, Analysis of data, Interpretation of data, Drafting the article, Final approval of the version to be published
Renata Pacholczak-Madej - Substantial contributions to conception and design, Acquisition of data, Analysis of data, Interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Elżbieta Łuczyńska - Acquisition of data, Analysis of data, Interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Joanna Niemiec - Revising it critically for important intellectual content, Final approval of the version to be published
Anna Mucha-Małecka - Acquisition of data, Interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Guaranter of SubmissionThe corresponding author is the guarantor of submission.
Source of SupportNone
Consent StatementWritten informed consent was obtained from the patient for publication of this article.
Data AvailabilityAll relevant data are within the paper and its Supporting Information files.
Conflict of InterestAuthors declare no conflict of interest.
Copyright© 2021 Aleksandra Grela-Wojewoda et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.
